Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | CFO AND TREASURER | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,876 |
Ending reported balance
After 2026-06-22 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 8,750 · Balance 27,626 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Row 2 · 2026-06-22 · Sale · Disposed 164 · Balance 27,462 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-06-22 · Sale · Disposed 865 · Balance 26,597 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-06-22 · Sale · Disposed 1,091 · Balance 25,506 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-06-22 · Sale · Disposed 840 · Balance 24,666 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-06-22 · Sale · Disposed 2,266 · Balance 22,400 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-06-22 · Sale · Disposed 1,994 · Balance 20,406 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-06-22 · Sale · Disposed 280 · Balance 20,126 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-06-22 · Sale · Disposed 1,250 · Balance 18,876 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-22 · Exercise / conversion · Disposed 8,750 · Balance 0 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 576 | $347.60 | $200,217.60 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,615 F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 576 of the resulting shares of common stock, and held the remaining 274 shares of common stock. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 850 | $117.76 | $100,096.00 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 576 of the resulting shares of common stock, and held the remaining 274 shares of common stock. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 557 | $347.60 | $193,613.20 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,341 F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 816 stock options, sold 557 of the resulting shares of common stock, and held the remaining 259 shares of common stock. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 816 | $120.26 | $98,132.16 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 816 stock options, sold 557 of the resulting shares of common stock, and held the remaining 259 shares of common stock. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,400 | $347.60 | $1,181,840.00 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,082 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,400 | $117.76 | $400,384.00 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,266 | $347.60 | $1,135,261.60 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,082 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,266 | $120.26 | $392,769.16 |
DisclosureSEC source: 0001415889-24-022228 · form4-08262024_040804.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 850 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · derivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,250 Underlying: Common Stock · 850 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 591 of the resulting shares of common stock, and held the remaining 259 shares of common stock. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 816 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · derivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,918 Underlying: Common Stock · 816 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 816 stock options, sold 571 of the resulting shares of common stock, and held the remaining 245 shares of common stock. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,400 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · derivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,100 Underlying: Common Stock · 3,400 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,266 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · derivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,734 Underlying: Common Stock · 3,266 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 591 | $329.02 | $194,450.82 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,082 F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 591 of the resulting shares of common stock, and held the remaining 259 shares of common stock. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 850 | $117.76 | $100,096.00 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 591 of the resulting shares of common stock, and held the remaining 259 shares of common stock. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 571 | $329.02 | $187,870.42 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,823 F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 816 stock options, sold 571 of the resulting shares of common stock, and held the remaining 245 shares of common stock. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 816 | $120.26 | $98,132.16 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 816 stock options, sold 571 of the resulting shares of common stock, and held the remaining 245 shares of common stock. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,400 | $329.02 | $1,118,668.00 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,578 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,400 | $117.76 | $400,384.00 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,266 | $329.02 | $1,074,579.32 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,578 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,266 | $120.26 | $392,769.16 |
DisclosureSEC source: 0001415889-24-021694 · form4-08202024_040802.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 15,160 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-013352 · form4-05162024_040509.xml · derivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Share Tracking Award · 15,160 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 25,000 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-013352 · form4-05162024_040509.xml · derivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Share Tracking Award · 25,000 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 15,160 | $272.69 | $4,133,980.40 |
DisclosureSEC source: 0001415889-24-013352 · form4-05162024_040509.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,578 Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,160 | $163.30 | $2,475,628.00 |
DisclosureSEC source: 0001415889-24-013352 · form4-05162024_040509.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 25,000 | $272.69 | $6,817,250.00 |
DisclosureSEC source: 0001415889-24-013352 · form4-05162024_040509.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,578 Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 25,000 | $163.30 | $4,082,500.00 |
DisclosureSEC source: 0001415889-24-013352 · form4-05162024_040509.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 26, 59, 47, and 62 shares of common stock acquired on September 2, 2022, March 3, 3023, September 1, 2023, and March 4, 2024, respectively, under the United Therapeutics Corporation Employee Stock Purchase Plan. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 10,380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001636178-26-000001 · primarydocument.xml · derivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,380 Underlying: Common Stock · 10,380 shares Expires not disclosed F5 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 9,098 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001636178-26-000001 · primarydocument.xml · derivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,098 Underlying: Common Stock · 9,098 shares Expires not disclosed F2 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 58,170 | $0.00 Strike: $217.50 | $0.00 |
DisclosureSEC source: 0001636178-26-000001 · primarydocument.xml · derivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,170 Underlying: Common Stock · 58,170 shares Expires 2033-03-15 F1 · security: These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 2,411 | $0.00 Strike: $94.96 | $0.00 |
DisclosureSEC source: 0001415889-22-011244 · form4-11092022_041154.xml · derivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Share Tracking Award · 2,411 shares Expires 2024-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of a share tracking award by the reporting person. Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 5,000 | $0.00 Strike: $52.12 | $0.00 |
DisclosureSEC source: 0001415889-22-011244 · form4-11092022_041154.xml · derivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Share Tracking Award · 5,000 shares Expires 2023-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of a share tracking award by the reporting person. Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 2,411 | $266.80 | $643,254.80 |
DisclosureSEC source: 0001415889-22-011244 · form4-11092022_041154.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,384 F1 · security: Exercise of a share tracking award by the reporting person. Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 2,411 | $94.96 | $228,948.56 |
DisclosureSEC source: 0001415889-22-011244 · form4-11092022_041154.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of a share tracking award by the reporting person. Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 5,000 | $266.80 | $1,334,000.00 |
DisclosureSEC source: 0001415889-22-011244 · form4-11092022_041154.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,384 F1 · security: Exercise of a share tracking award by the reporting person. Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 5,000 | $52.12 | $260,600.00 |
DisclosureSEC source: 0001415889-22-011244 · form4-11092022_041154.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of a share tracking award by the reporting person. Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F2 · balance_after: Includes 23 shares acquired on September 4, 2019, 297 shares acquired on March 4, 2020, 156 shares acquired on March 4, 2021, 58 shares acquired on September 3, 2021, 97 shares acquired on March 4, 2022 and 26 shares acquired on September 2, 2022, under the United Therapeutics Corporation Employee Stock Purchase Plan. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 12:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 162,500 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001127602-19-011995 · form4.xml · derivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2027-03-15 F2 · security: These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. F5 · derivative.exercise_date: These stock options will vest in equal one-third installments on March 15, 2021, 2022 and 2023. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 12:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 162,500 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001127602-19-011995 · form4.xml · derivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2027-03-15 F2 · security: These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. F3 · derivative.exercise_price: Exercise price is equal to 115% of the closing price for the Company's common stock on the date of grant. F4 · derivative.exercise_date: This award will cliff vest (100%) on March 15, 2023. Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 22:45 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 56,512 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008756 · form4.xml · derivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,512 Underlying: Common Stock · 56,512 shares Expires 2028-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2018, subject to a one-year performance condition tied to company-wide milestone performance for 2018, which was determined on February 27, 2019. Number of stock options reported represents the number of options earned based on milestone performance. F3 · derivative.exercise_date: These stock options vest in one-third increments on each of March 15, 2019, 2020 and 2021. Read SEC document |
| March 15, 2018 Filed Mar 16, 2021 23:00 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 75,349 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001127602-21-010885 · form4a.xml · derivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,349 Underlying: Common Stock · 75,349 shares Expires 2028-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profit margin during 2018-2020, which was determined on February 24, 2021. Number of stock options reported represents the number of options earned based on performance. F3 · derivative.expiration_date: This Form 4/A is being filed to correct the expiration date of this award. Read SEC document |
| March 15, 2018 Filed Mar 16, 2021 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 75,349 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001127602-21-010812 · form4.xml · derivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,349 Underlying: Common Stock · 75,349 shares Expires 2018-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profit margin during 2018-2020, which was determined on February 24, 2021. Number of stock options reported represents the number of options earned based on performance. Read SEC document |
| February 21, 2018 Filed Feb 26, 2018 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 32,205 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-18-008399 · form4.xml · derivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,205 Underlying: Common Stock · 32,205 shares Expires 2027-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2017, subject to a one-year performance condition tied to company-wide milestone performance for 2017, which was determined on February 21, 2018. Number of stock options reported represents the number of options earned based on milestone performance. F3 · derivative.exercise_date: These stock options vest in one-third increments on each of March 15, 2018, 2019 and 2020. Read SEC document |
| March 15, 2017 Filed Mar 15, 2017 22:14 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 45,000 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-17-011820 · form4.xml · derivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-03-15 F1 · derivative.exercise_date: These stock options vest in one-third increments on each of March 15, 2018, 2019 and 2020. Read SEC document |
| March 15, 2017 Filed Mar 16, 2020 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 52,312 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-20-010804 · form4.xml · derivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,312 Underlying: Common Stock · 52,312 shares Expires 2027-03-15 F3 · security: These performance-based stock options were initially awarded on March 15, 2017, subject to a three-year performance condition tied to average cash profits during 2017-2019, which was determined on February 26, 2020. Number of stock options reported represents the number of options earned based on performance. Read SEC document |
| March 15, 2017 Filed Mar 16, 2020 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 18,750 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-20-010804 · form4.xml · derivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2027-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2017, subject to a three-year performance condition tied to average cash profits during 2017-2019, which was determined on February 26, 2020. Number of stock options reported represents the number of options earned based on performance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.